Arexvy vaccine
This product is manufactured by GlaxoSmithKline using the ingredient respiratory syncytial virus (RSV) Vaccine - recombinant with adjuvant.
This product is taken via intramuscular injection.
Why is it prescribed?
The RSV vaccine is indicated for use in adults 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV.
Vaccination with Arexvy should occur before onset of RSV season but may be given anytime during the season if appropriate.
Although Arexvy can be given to any person over the age of 60 years, it is particularly important for people who have risk factors for severe outcomes due to RSV infections, such as:
- Heart disease
- Lung disease
- Metabolic disease
- Advanced liver or kidney disease
- Moderate or severe immune compromise
- Neurologic or neuromuscular conditions
- Blood disorders
- Advanced age or frailty
Alternatives
See other products used in the treatment of •Respiratory Syncytial Virus (RSV) •
Arexvy is given as an intramuscular injection - preferably in the deltoid muscle. The dosage is a single dose of 0.5 ml.
The RSV vaccine helps the body make antibodies and white blood cells that fight against the RSV-A or RSV-B subtypes in adults aged 60 years and older. The RSV virus can can cause severe influenza-like illness and lower respiratory tract illness in some people.
Very common: pain at the injection site, tiredness, headache, muscle pain
Common: redness and swelling at the injection site, fever, chills, runny nose
Uncommon: injection site itching, pain, generally feeling unwell, swelling of lymph nodes, rash, nausea, stomach pain
Do not get this vaccine if you have:
- had previous life-threatening allergic reaction to any component of the vaccine (check with your health care provider for vaccine ingredients)
- a serious illness with a high temperature. A minor infection such as a cold, including mild fever, should not require you to postpone the vaccination.